BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee ST, Lee DH, Lim JH, Kim N, Park YS, Shin CM, Jo HJ, Song IS. Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection. Gut Liver. 2015;9:478-485. [PMID: 25071068 DOI: 10.5009/gnl14020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Park JY, Kim JG. [New Helicobacter pylori Eradication Therapies]. Korean J Gastroenterol 2018;72:237-44. [PMID: 30642139 DOI: 10.4166/kjg.2018.72.5.237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Kim SB, Lee SH, Kim KO, Jang BI, Kim TN. [Ten-day Sequential Therapy versus Bismuth Based Quadruple Therapy as Second Line Treatment for Helicobacter pylori Infection]. Korean J Gastroenterol 2015;66:261-7. [PMID: 26586348 DOI: 10.4166/kjg.2015.66.5.261] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
3 Gisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter. 2017;22. [PMID: 28464347 DOI: 10.1111/hel.12392] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 7.4] [Reference Citation Analysis]
4 Goderska K, Agudo Pena S, Alarcon T. Helicobacter pylori treatment: antibiotics or probiotics. Appl Microbiol Biotechnol. 2018;102:1-7. [PMID: 29075827 DOI: 10.1007/s00253-017-8535-7] [Cited by in Crossref: 67] [Cited by in F6Publishing: 56] [Article Influence: 13.4] [Reference Citation Analysis]
5 Kahramanoğlu Aksoy E, Pirinçci Sapmaz F, Göktaş Z, Uzman M, Nazlıgül Y. Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen. Med Princ Pract 2017;26:523-9. [PMID: 29131124 DOI: 10.1159/000484930] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
6 Altun B, Ozturk K. Efficiency of Moxifloxacin in the Treatment of Helicobacter pylori Infection. Gut Liver 2015;9:809-10. [PMID: 26087796 DOI: 10.5009/gnl14469] [Reference Citation Analysis]
7 Nyssen OP, Perez-Aisa A, Rodrigo L, Castro M, Mata Romero P, Ortuño J, Barrio J, Huguet JM, Modollel I, Alcaide N, Lucendo A, Calvet X, Perona M, Gomez B, Gomez Rodriguez BJ, Varela P, Jimenez-Moreno M, Dominguez-Cajal M, Pozzati L, Burgos D, Bujanda L, Hinojosa J, Molina-Infante J, Di Maira T, Ferrer L, Fernández-Salazar L, Figuerola A, Tito L, de la Coba C, Gomez-Camarero J, Fernandez N, Caldas M, Garre A, Resina E, Puig I, O'Morain C, Megraud F, Gisbert JP. Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg). Helicobacter 2020;25:e12722. [PMID: 32656898 DOI: 10.1111/hel.12722] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 O'Connor A, Gisbert JP, O'Morain C, Ladas S. Treatment of Helicobacter pylori Infection 2015. Helicobacter. 2015;20 Suppl 1:54-61. [PMID: 26372826 DOI: 10.1111/hel.12258] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
9 Lee JW, Kim N, Nam RH, Lee SM, Soo In C, Kim JM, Lee DH. Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradication. Journal of Gastroenterology and Hepatology 2019;34:666-72. [DOI: 10.1111/jgh.14625] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
10 Su J, Zhou X, Chen H, Hao B, Zhang W, Zhang G. Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial. Medicine (Baltimore) 2017;96:e5859. [PMID: 28207505 DOI: 10.1097/MD.0000000000005859] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
11 Liao XM, Nong GH, Chen MZ, Huang XP, Cong YY, Huang YY, Wu BH, Wei JQ. Modified sequential therapy vs quadruple therapy as initial therapy in patients with Helicobacter infection. World J Gastroenterol 2015; 21(20): 6310-6316 [PMID: 26034367 DOI: 10.3748/wjg.v21.i20.6310] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
12 Kim SE, Park MI, Park SJ, Moon W, Kim JH, Jung K, Kim HK, Lee YD. Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes. World J Gastroenterol 2017; 23(6): 1059-1066 [PMID: 28246480 DOI: 10.3748/wjg.v23.i6.1059] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
13 Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6-30. [PMID: 27707777 DOI: 10.1136/gutjnl-2016-312288] [Cited by in Crossref: 1166] [Cited by in F6Publishing: 992] [Article Influence: 194.3] [Reference Citation Analysis]
14 Kim SE, Roh JH, Park MI, Park SJ, Moon W, Kim JH, Jung K, Heo JJ. Effect of 7-day Bismuth Quadruple Therapy versus 14-day Moxifloxacin Triple Therapy for Second-line Helicobacter pylori Eradication Therapy. Korean J Gastroenterol 2019;73:26. [DOI: 10.4166/kjg.2019.73.1.26] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
15 Graham DY, Lee SY. How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly. Gastroenterol Clin North Am. 2015;44:537-563. [PMID: 26314667 DOI: 10.1016/j.gtc.2015.05.003] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 9.7] [Reference Citation Analysis]
16 Mori H, Suzuki H. Update on quinolone-containing rescue therapies for Helicobacter pylori infection. World J Gastroenterol 2020; 26(15): 1733-1744 [PMID: 32351290 DOI: 10.3748/wjg.v26.i15.1733] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]